1. Home
  2. LCNB vs MDXH Comparison

LCNB vs MDXH Comparison

Compare LCNB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$16.34

Market Cap

205.5M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.66

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
MDXH
Founded
1877
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
205.5M
167.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LCNB
MDXH
Price
$16.34
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
25.0K
124.4K
Earning Date
01-29-2026
02-26-2026
Dividend Yield
5.38%
N/A
EPS Growth
220.73
N/A
EPS
1.67
N/A
Revenue
$89,312,000.00
$103,069,000.00
Revenue This Year
$18.04
$23.34
Revenue Next Year
$4.36
$22.98
P/E Ratio
$9.81
N/A
Revenue Growth
19.58
21.68
52 Week Low
$13.34
$1.35
52 Week High
$17.84
$5.33

Technical Indicators

Market Signals
Indicator
LCNB
MDXH
Relative Strength Index (RSI) 51.79 57.67
Support Level $16.14 $3.00
Resistance Level $16.74 $3.43
Average True Range (ATR) 0.37 0.22
MACD -0.05 0.05
Stochastic Oscillator 56.76 87.84

Price Performance

Historical Comparison
LCNB
MDXH

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: